{"text": "Supplementary Material\n\nSupplementary Table 1 Demographic and clinical characteristics of study patients and stable weekly doses (SWDs) of warfarin\n\nINR, international normalized ratio; DVT or PE or CTEPH, deep vein thrombosis or pulmonary embolism or chronic thromboembolic pulmonary hypertension\n\n* Antiplatelet drugs include clopidoglel or prasugrel or ticagrelor.\n\nCharacteristics  Number (%) ormean  SD (range)  Stable weekly dose (mg) mean  SD  p value    Gender             Male  129 (51.6)  22.3  9.6  0.998       Female  121 (48.4)  22.2  8.9      Age (years)             &lt; 65 years  144 (57.6)  24.2  9.3  &lt;0.001       &ge; 65 years  106 (42.4)  19.6  8.5      Body mass index (kg/m2)             &lt; 30 kg/m2  226 (90.4)  21.8  9.0  0.007       &ge; 30 kg/m2  24 (9.6)  27.2  9.9      Current smoker                No   237 (94.8)  22.1  8.9  0.417          Yes  13 (5.2)  25.9  13.8      Current alcohol drinker                No   231 (92.4)  22.2  9.5  0.203          Yes  19 (7.6)  23.1  6.1      Indication             Atrial fibrillation                No   82 (32.8)  25.1  10.0  0.001          Yes  168 (67.2)  20.9  8.5         Valve replacement or valvular heart disease                No   205 (82.0)  21.9  9.1  0.129          Yes  45 (18.0)  24.2  9.9      DVT or PE or CTEPH                 No   236 (94.4)  21.9  9.1  0.006       Yes  14 (5.6)  29.0  9.3         Others (e.g. cardiomyopathy,        atrial septal defect)   23 (9.2)        Comorbidity             Hypertension                Absent  194 (77.6)  22.3  9.4  0.925          Present     56 (22.4)  22.2  8.9         Diabetes mellitus                Absent  215 (86.0)  22.3  9.3  0.956          Present     35 (14.0)  22.3  8.9         Dyslipidemia                Absent  234 (93.6)  22.2  9.3  0.477          Present     16 (6.4)  23.7  8.9         Congestive heart failure                Absent  244 (97.6)  22.3  9.3  0.934          Present     6 (2.4)  21.9  9.0         History of stroke                 Absent  231 (92.4)  22.5  9.4  0.099           Present     19 (7.6)  19.0  6.9      Concomitant medication              Amiodarone                No   234 (93.6)  22.6  9.3  0.033          Yes  16 (6.4)  17.2  7.6            Antiplatelet drugs*                No   226 (90.4)  22.8  9.2  0.003          Yes  24 (9.6)  17.6  8.9         Aspirin                No   214 (85.6)  22.5  9.3  0.372          Yes  36 (14.4)  21.1  8.8         Angiotensin converting enzyme inhibitors                 No   212 (84.8)  22.6  9.3  0.147          Yes  38 (15.2)  20.7  8.7         Angiotensin II receptor blockers                No   208 (83.2)  21.9  9.1  0.178          Yes  42 (16.8)  24.3  9.6         Beta blockers                 No   114 (45.6)  23.1  9.4  0.198           Yes  136 (54.4)  21.6  9.1         Calcium channel blockers                No   213 (85.2)  22.3  9.3  0.628          Yes  37 (14.8)  22.2  9.3         Digoxin                No   179 (71.6)  23.0  9.7  0.125          Yes  71 (28.4)  20.4  7.8         Diuretics                No   124 (49.6)  22.1  8.9  0.851          Yes  126 (50.4)  22.4  9.7         Proton pump inhibitors                No   213 (85.2)  22.7  9.4  0.065          Yes  37 (14.8)  19.7  8.1         Statins                No   145 (58.0)  22.9  9.2  0.206          Yes  105 (42.0)  21.5  9.3"}